These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 34915673)

  • 1. Chemically modified mRNA beyond COVID-19: Potential preventive and therapeutic applications for targeting chronic diseases.
    Elkhalifa D; Rayan M; Negmeldin AT; Elhissi A; Khalil A
    Biomed Pharmacother; 2022 Jan; 145():112385. PubMed ID: 34915673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic modified messenger RNA for therapeutic applications.
    Gao M; Zhang Q; Feng XH; Liu J
    Acta Biomater; 2021 Sep; 131():1-15. PubMed ID: 34133982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opportunities and Challenges for mRNA Delivery Nanoplatforms.
    Zhang Y; Hu Y; Tian H; Chen X
    J Phys Chem Lett; 2022 Feb; 13(5):1314-1322. PubMed ID: 35107010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A network analysis of COVID-19 mRNA vaccine patents.
    Gaviria M; Kilic B
    Nat Biotechnol; 2021 May; 39(5):546-548. PubMed ID: 33981074
    [No Abstract]   [Full Text] [Related]  

  • 5. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
    Huang Q; Ji K; Tian S; Wang F; Huang B; Tong Z; Tan S; Hao J; Wang Q; Tan W; Gao GF; Yan J
    Nat Commun; 2021 Feb; 12(1):776. PubMed ID: 33536425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mRNA vaccines for COVID-19 and diverse diseases.
    Hussain A; Yang H; Zhang M; Liu Q; Alotaibi G; Irfan M; He H; Chang J; Liang XJ; Weng Y; Huang Y
    J Control Release; 2022 May; 345():314-333. PubMed ID: 35331783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mRNA vaccine development and applications: A special focus on tumors (Review).
    Chen B; Yang Y; Wang X; Yang W; Lu Y; Wang D; Zhuo E; Tang Y; Su J; Tang G; Shao S; Gu K
    Int J Oncol; 2024 Aug; 65(2):. PubMed ID: 38994758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
    Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
    Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across.
    Minnaert AK; Vanluchene H; Verbeke R; Lentacker I; De Smedt SC; Raemdonck K; Sanders NN; Remaut K
    Adv Drug Deliv Rev; 2021 Sep; 176():113900. PubMed ID: 34324884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer mRNA vaccines: clinical advances and future opportunities.
    Sayour EJ; Boczkowski D; Mitchell DA; Nair SK
    Nat Rev Clin Oncol; 2024 Jul; 21(7):489-500. PubMed ID: 38760500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants.
    Qu P; Faraone JN; Evans JP; Zheng YM; Yu L; Ma Q; Carlin C; Lozanski G; Saif LJ; Oltz EM; Gumina RJ; Liu SL
    N Engl J Med; 2022 Oct; 387(14):1329-1331. PubMed ID: 36069925
    [No Abstract]   [Full Text] [Related]  

  • 13. mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy.
    Deng Z; Tian Y; Song J; An G; Yang P
    Front Immunol; 2022; 13():887125. PubMed ID: 35720301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype.
    Pascolo S
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33572452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research progress on the quality control of mRNA vaccines.
    Hu C; Bai Y; Liu J; Wang Y; He Q; Zhang X; Cheng F; Xu M; Mao Q; Liang Z
    Expert Rev Vaccines; 2024; 23(1):570-583. PubMed ID: 38733272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 mRNA vaccines.
    Huang Q; Zeng J; Yan J
    J Genet Genomics; 2021 Feb; 48(2):107-114. PubMed ID: 34006471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent progress.
    Cell; 2021 Oct; 184(21):5293-5296. PubMed ID: 34562365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Messenger RNA Vaccines: Beckoning of a New Era in Cancer Immunotherapy.
    Copur M
    Oncology (Williston Park); 2021 Apr; 35(4):190-198. PubMed ID: 33893760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination.
    Sisteré-Oró M; Wortmann DDJ; Andrade N; Aguilar A; Mayo de Las Casas C; Casabal FG; Torres S; Bona Salinas E; Raventos Soler L; Arcas A; Esparre C; Garcia B; Valarezo J; Rosell R; Güerri-Fernandez R; Gonzalez-Cao M; Meyerhans A
    Front Immunol; 2022; 13():908108. PubMed ID: 35911701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 mRNA vaccines: Platforms and current developments.
    Szabó GT; Mahiny AJ; Vlatkovic I
    Mol Ther; 2022 May; 30(5):1850-1868. PubMed ID: 35189345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.